ITC and also by biolayer interferometry
I-CBP112 displaced acetylated lysine peptides from CBP with an IC50 = 170 nM.
PDB ID for probe-target interaction (3D structure):
4NR6
Potency (off target):
KD
Off target protein and potency:
BRD4 (1) 5.6 uM (2) 20 uM
Potency assay (off target):
ITC, and using biointerferometry, I-CBP112 did not bind to any additional of 40 Bromodomains tested.
Probe Selectivity in Vitro:
Minimal activity against 104 proteins (nuclear receptors, ion channels, kinases, proteases, and phosphodiesterases). I-CBP112 interacted weakly with two GPCRs: alpha1A and 5HT1.
In cell validation
Potency in cells:
IC50
600 nM
Potency assay (cells):
In cells, I-CBP112 interfered with CBP interaction with acetylated lysine-containing proteins in FRAP and BRET assays.
Target engagement assay (cells):
Indirect: FRAP and BRET assays
In vivo validation
Organism:
mice
Dose:
3 mg/mL
Route of delivery:
Intraperitoneal
Plasma half life:
0.6 hr
Cmax:
590 ng/mL
Organ (O):
bone marrow transplant with MLL-AF9 leukemia cells